In vivo 1H MR spectroscopic imaging of aggressive prostate cancer: Can we detect lactate?

Magnetic Resonance in Medicine

Volumn 71, Issue 1, 2014, Pages 26-34

  Kobus, Thiele ^a   Wright, Alan J ^a   Van Asten, Jack J A ^a   Heerschap, Arend ^a   Scheenen, Tom W J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

lactate; prostate cancer; semi LASER

Indexed keywords

CELL DEATH; ITERATIVE METHODS; TUMORS; UROLOGY;

BIOPSY SAMPLES; GLEASON SCORES; LACTATE; LACTATE CONCENTRATION; LOW CONCENTRATIONS; MR SPECTROSCOPIC IMAGING; PATIENT SPECIFIC; PROSTATE CANCERS;

DISEASES;

CHOLINE; CITRIC ACID; CREATINE; LACTIC ACID; SPERMINE;

ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; GLEASON SCORE; HUMAN; HUMAN TISSUE; HYPOXIA; IN VIVO STUDY; LIMIT OF DETECTION; MALE; PROSTATE BIOPSY; PROSTATE CANCER; PROTON NUCLEAR MAGNETIC RESONANCE; RELAXATION TIME; SIGNAL NOISE RATIO; SIMULATION;

1H MRSI; LACTATE; PROSTATE CANCER; SEMI-LASER;

AGED; AGED, 80 AND OVER; ALGORITHMS; COMPUTER SIMULATION; HUMANS; LACTIC ACID; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MODELS, BIOLOGICAL; PROSTATIC NEOPLASMS; PROTONS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84890794555     PISSN: 07403194     EISSN: 15222594     Source Type: Journal    
DOI: 10.1002/mrm.24635     Document Type: Article

References (47)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Schröder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. New Engl J Med 2012; 366: 981-990.
3. Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RAM, Schröder FH, de Koning HJ,. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European randomized study of screening for prostate cancer. J Natl Cancer I 2003; 95: 868-878.
4. Heerschap A, Jager GJ, Van Der Graaf M, Barentsz JO, De La Rosette JJMCH, Oosterhof GON, Ruijter ETG, Ruijs SHJ,. In vivo proton MR spectroscopy reveals altered metabolite content in malignant prostate tissue. Anticancer Res 1997; 17: 1455-1460.
5. Kurhanewicz J, Vigneron DB, Nelson SJ, Hricak H, MacDonald JM, Konety B, Narayan P,. Citrate as an in vivo marker to discriminate prostate cancer from benign prostatic hyperplasia and normal prostate peripheral zone: detection via localized proton spectroscopy. Urology 1995; 45: 459-466.
6. 3) spatial resolution. Radiology 1996; 198: 795-805.
7. Kobus T, Hambrock T, Hulsbergen-Van De Kaa CA, Wright AJ, Barentsz JO, Heerschap A, Scheenen TWJ,. In vivo assessment of prostate cancer aggressiveness using magnetic resonance spectroscopic imaging at 3 T with an endorectal coil. Eur Urol 2011; 60: 1074-1080.
8. Zakian KL, Sircar K, Hricak H, et al. Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology 2005; 234: 804-814.
9. Wilson WR, Hay MP,. Targeting hypoxia in cancer therapy. Nat Rev Cancer 2011; 11: 393-410.
10. Hirschhaeuser F, Sattler UGA, Mueller-Klieser W,. Lactate: a metabolic key player in cancer. Cancer Res 2011; 71: 6921-6925.
11. Walenta S, Mueller-Klieser WF,. Lactate: mirror and motor of tumor malignancy. Semin Radiat Oncol 2004; 14: 267-274.
12. Hoskin PJ, Carnell DM, Taylor NJ, et al. Hypoxia in prostate cancer: correlation of BOLD-MRI with pimonidazole immunohistochemistry-initial observations. Int J Radiat Oncol Biol Phys 2007; 68: 1065-1071.
13. Tessem MB, Swanson MG, Keshari KR, et al. Evaluation of lactate and alanine as metabolic biomarkers of prostate cancer using 1H HR-MAS spectroscopy of biopsy tissues. Magn Reson Med 2008; 60: 510-516.
14. Verma S, Rajesh A, Fütterer JJ, Turkbey B, Scheenen TWJ, Pang Y, Choyke PL, Kurhanewicz J,. Prostate MRI and 3D MR spectroscopy: how we do it? AJR Am J Roentgenol 2010; 194: 1414-1426.
15. Lange T, Dydak U, Roberts TPL, Rowley HA, Bjeljac M, Boesiger P,. Pitfalls in lactate measurements at 3T. AJNR Neuroradiol 2006; 27: 895-901.
16. nd ed. Chichester, UK: Wiley; 2007.
17. Slotboom J, Bovee W,. Adiabatic slice-selective Rf pulses and a single-shot adiabatic localization pulse sequence. Concepts Magn Resonance 1995; 7: 193-217.
18. Scheenen TWJ, Klomp DWJ, Wijnen JP, Heerschap A,. Short echo time 1H-MRSI of the human brain at 3T with minimal chemical shift displacement errors using adiabatic refocusing pulses. Magn Reson Med 2008; 59: 1-6.
19. Scheenen TWJ, Heerschap A, Klomp DWJ,. Towards 1H-MRSI of the human brain at 7T with slice-selective adiabatic refocusing pulses. Magn Reson Mater Phy 2008; 21: 95-101.
20. Tannus A, Garwood M,. Improved performance of frequency-swept pulses using offset-independent adiabaticity. J Magn Reson Ser A 1996; 120: 133-137.
21. Govindaraju V, Young K, Maudsley AA,. Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed 2000; 13: 129-153.
22. Moore GJ, Sillerud LO,. The pH dependence of chemical shift and spin-spin coupling for citrate. J Magn Reson B 1994; 103: 87-88.
23. Van der Graaf M, Heerschap A,. Effect of cation binding on the proton chemical shifts and the spin-spin coupling constant of citrate. J Magn Reson B 1996; 112: 58-62.
24. Scheenen TWJ, Gambarota G, Weiland E, Klomp DWJ, Fütterer JJ, Barentsz JO, Heerschap A,. Optimal timing for in vivo 1H-MR spectroscopic imaging of the human prostate at 3T. Magn Reson Med 2005; 53: 1268-1274.
25. Van der Graaf M, Jager GJ, Heerschap A,. Removal of the outer lines of the citrate multiplet in proton magnetic resonance spectra of the prostatic gland by accurate timing of a point-resolved spectroscopy pulse sequence. Magn Reson Mater Phy 1997; 5: 65-69.
26. Scheenen TW, Heijmink SW, Roell SA, Hulsbergen-Van de Kaa CA, Knipscheer BC, Witjes JA, Barentsz JO, Heerschap A,. Three-dimensional proton MR spectroscopy of human prostate at 3 T without endorectal coil: feasibility. Radiology 2007; 245: 507-516.
27. Jung JA, Coakley FV, Vigneron DB, Swanson MG, Qayyum A, Weinberg V, Jones KD, Carroll PR, Kurhanewicz J,. Prostate depiction at endorectal MR spectroscopic imaging: investigation of a standardized evaluation system. Radiology 2004; 233: 701-708.
28. Fütterer JJ, Scheenen TWJ, Heijmink SWTPJ, Huisman HJ, Hulsbergen-Van De Kaa CA, Witjes JA, Heerschap A, Barentsz JO,. Standardized threshold approach using three-dimensional proton magnetic resonance spectroscopic imaging in prostate cancer localization of the entire prostate. Invest Radiol 2007; 42: 116-122.
29. Provencher SW,. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 1993; 30: 672-679.
30. Provencher SW. LCModel & LCMgui User's Manual 2009.
31. Bolan PJ, Meisamy S, Baker EH, Lin J, Emory T, Nelson M, Everson LI, Yee D, Garwood M,. In vivo quantification of choline compounds in the breast with 1H MR spectroscopy. Magn Reson Med 2003; 50: 1134-1143.
32. Heerschap A, Jager GJ, Van Der Graaf M, Barentsz JO, Ruijs SHJ,. Proton MR spectroscopy of the normal human prostate with an endorectal coil and a double spin-echo pulse sequence. Magn Reson Med 1997; 37: 204-213.
33. Sappey-Marinier D, Calabrese G, Hetherington HP, Fisher SNG, Deicken R, Van Dyke C, Fein G, Weiner MW,. Proton magnetic resonance spectroscopy of human brain: applications to normal white matter, chronic infarction, and MRI white matter signal hyperintensities. Magn Reson Med 1992; 26: 313-327.
34. Kreis R, Ernst T, Ross BD,. Development of the human brain: in vivo quantification of metabolite and water content with proton magnetic resonance spectroscopy. Magn Reson Med 1993; 30: 424-437.
35. Frahm J, Bruhn H, Gyngell ML, Merboldt KD, Hanicke W, Sauter R,. Localized proton NMR spectroscopy in different regions of the human brain in vivo. Relaxation times and concentrations of cerebral metabolites. Magn Reson Med 1989; 11: 47-63.
36. Howe FA, Barton SJ, Cudlip SA, et al. Metabolic profiles of human brain tumors using quantitative in vivo 1H magnetic resonance spectroscopy. Magn Reson Med 2003; 49: 223-232.
37. Kuesel AC, Sutherland GR, Halliday W, Smith ICP,. 1H MRS of high grade astrocytomas: mobile lipid accumulation in necrotic tissue. NMR Biomed 1994; 7: 149-155.
38. Fajardo DA, Miyamoto H, Miller JS, Lee TK, Epstein JI,. Identification of gleason pattern 5 on prostatic needle core biopsy: frequency of underdiagnosis and relation to morphology. Am J Surg Pathol 2011; 35: 1706-1711.
39. Padhani AR, Liu G, Mu-Koh D, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 2009; 11: 102-125.
40. Van Asten JJA, Cuijpers V, Hulsbergen-Van De Kaa C, Soede-Huijbregts C, Witjes JA, Verhofstad A, Heerschap A,. High resolution magic angle spinning NMR spectroscopy for metabolic assessment of cancer presence and Gleason score in human prostate needle biopsies. Magn Reson Mater Phy 2008; 21: 435-442.
41. Swanson MG, Zektzer AS, Tabatabai ZL, et al. Quantitative analysis of prostate metabolites using 1H HR-MAS spectroscopy. Magn Reson Med 2006; 55: 1257-1264.
42. Reinicke K, Sotomayor P, Cisterna P, Delgado C, Nualart F, Godoy A,. Cellular distribution of glut-1 and glut-5 in benign and malignant human prostate tissue. J Cell Biochem 2012; 113: 553-562.
43. Albers MJ, Bok R, Chen AP, et al. Hyperpolarized 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading. Cancer Res 2008; 68: 8607-8615.
44. Nelson SJ, Kurhanewicz J, Vigneron D, et al. Proof of concept clinical trial of hyperpolarized C-13 pyruvate in patients with prostate cancer. In Proceedings of the 20th Annual Meeting of the ISMRM, Melbourne, Australia, 2012. Abstract 274.
45. Schiebler ML, Miyamoto KK, White M, Maygarden SJ, Mohler JL,. In vitro high resolution 1H-spectroscopy of the human prostate: benign prostatic hyperplasia, normal peripheral zone and adenocarcinoma. Magn Reson Med 1993; 29: 285-291.
46. Hobarth K, Hofbauer J, Fang-Kircher S,. Plasma sialic acid in patients with prostate cancer. Brit J Urol 1993; 72: 621-624.
47. Lagana A, Pardo-Martinez B, Marino A, Fago G, Bizzarri M,. Determination of serum total lipid and free N-acetylneuraminic acid in genitourinary malignancies by fluorimetric high performance liquid chromatography. Relevance of free N-acetylneuraminic acid as tumour marker. Clin Chim Acta 1995; 243: 165-179.